Jason Bradley Terrell Md - Nov 3, 2021 Form 4 Insider Report for VOLITIONRX LTD (VNRX)

Role
Chief Medical Officer
Signature
/s/ Jason Terrell MD
Stock symbol
VNRX
Transactions as of
Nov 3, 2021
Transactions value $
$0
Form type
4
Date filed
11/5/2021, 04:05 PM
Previous filing
Jun 2, 2021
Next filing
Dec 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNRX Stock Option (Right to Buy) Disposed to Issuer -25K -100% 0 Nov 3, 2021 Common Stock 25K $4.00 Direct F1
transaction VNRX Stock Option (Right to Buy) Award +25K 25K Nov 3, 2021 Common Stock 25K $4.00 Direct F1
transaction VNRX Stock Option (Right to Buy) Disposed to Issuer -50K -100% 0 Nov 3, 2021 Common Stock 50K $5.00 Direct F2
transaction VNRX Stock Option (Right to Buy) Award +50K 50K Nov 3, 2021 Common Stock 50K $5.00 Direct F2
transaction VNRX Stock Option (Right to Buy) Disposed to Issuer -50K -100% 0 Nov 3, 2021 Common Stock 50K $4.00 Direct F3
transaction VNRX Stock Option (Right to Buy) Award +50K 50K Nov 3, 2021 Common Stock 50K $4.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).
F2 The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).
F3 The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).